KIA
REGN icon

Kopp Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Kopp Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,451
Closed -$1.34M – 73
2014
Q1 		$1.34M Sell
4,451
-146
-3% -$45K 0.56% 33
2013
Q4 		$1.26M Sell
4,597
-372
-7% -$107K 0.57% 32
2013
Q3 		$1.55M Sell
4,969
-994
-17% -$261K 0.57% 39
2013
Q2 		$1.34M Buy
+5,963
New +$1.39M 0.52% 37

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kopp Investment Advisors's REGN Position: Q2 2014 in Review

Kopp Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2014, closing a stake of 4,451 shares — an estimated $1.34M sold.

Kopp Investment Advisors first reported a position in REGN in Q2 2013 and held it in 4 quarters. The position peaked at $1.55M in Q3 2013. 448 funds tracked by Wall St. Rank hold REGN as of Q2 2014.

  • Kopp Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Kopp Investment Advisors sold 4,451 Regeneron Pharmaceuticals shares in Q2 2014, an estimated $1.34M.
  • Kopp Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Kopp Investment Advisors's Regeneron Pharmaceuticals position peaked at $1.55M in Q3 2013.
  • 448 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2014.

Based on Kopp Investment Advisors's 13F filing for Q2 2014, filed 1 Aug 2014.